| Primary | Percentage of Participants With a Reduction of at Least 2 log10 International Unit/Millilitres (IU/mL) in Hepatitis B Surface Antigen (HBsAg) Levels From Baseline to Week 24 | Percentage of participants with a reduction of at least 2 log10IU/mL in HBsAg levels from baseline to Week 24 were reported. A responder was defined as a participant with reduction of at least 2 log10 IU/mL in HBsAg levels from baseline at Week 24. | Full Analysis Set (FAS) included all participants who were enrolled and who received at least 1 dose of study intervention within this intervention-specific appendix (ISA). Data for this outcome measure was planned to be collected and analyzed for specified arm only. | Posted | | Number | 90% Confidence Interval | percentage of participants | | From Baseline (Day 1) to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only. |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG00064.6± 51.73(51.73 to 76.02)
|
|
| |
| Secondary | Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability | Percentage of participants with TEAEs were reported. An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were AEs with onset during the intervention period or follow-up period or that were a consequence of a pre-existing condition that had worsened since baseline. | Safety analysis set included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received. | Posted | | Number | | percentage of participants | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. |
|
| Secondary | Percentage of Participants With Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability | An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were AEs with onset during the intervention period or follow-up period or that were a consequence of a pre-existing condition that had worsened since baseline. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. | Safety analysis set included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received. | Posted | | Number | | percentage of participants | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. |
|
| Secondary | Number of Participants With Clinically Significant Abnormalities in Vital Signs as a Measure of Safety and Tolerability | Number of participants with clinically significant abnormalities in vital signs (pulse rate, and blood pressure [systolic and diastolic]) were reported. | Safety analysis set included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received. | Posted | | Count of Participants | | Participants | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. | | OG001 |
|
| Secondary | Number of Participants With Clinically Significant Abnormalities in Laboratory Findings as a Measure of Safety and Tolerability | Number of participants with clinically significant abnormalities in laboratory findings (including hematology, blood biochemistry, and urinalysis) were reported. Only parameters in which any participant had abnormality are reported below. | Safety analysis set included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this endpoint and "n"(number analyzed) signifies number of participants analyzed at specified timepoints. | Posted | | Count of Participants | | Participants | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. |
|
| Secondary | Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECGs) as a Measure of Safety and Tolerability | Number of participants with clinically significant abnormalities in 12- lead ECGs (heart rate, PR, QRS and QT corrected [QTc]) were reported. | Safety analysis set included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received. | Posted | | Count of Participants | | Participants | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to Week 28 | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. | | OG001 | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA |
|
| Secondary | Number of Participants With Clinically Significant Abnormalities in Physical Examination as a Measure of Safety and Tolerability | Number of participants with clinically significant abnormalities in physical examination were reported. | Safety analysis set included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received. Data for this outcome measure was not planned to be collected and analyzed for Follow-Up Period as pre-specified in protocol. | Posted | | Count of Participants | | Participants | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. | | OG001 | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA |
|
| Secondary | Number of Participants With Abnormalities in Ophthalmic Examination as a Measure of Safety and Tolerability | Number of participants with abnormalities in Ophthalmic examination were planned to be reported. | Safety analysis set included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received. Data for this outcome measure was planned to be collected and analyzed at TP 1 and TP 2 for participants with diabetes/hypertension only. Since no subject had diabetes/hypertension hence data for this OM was not collected and analyzed as pre-specified in protocol. | Posted | | | | | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. | | OG001 |
|
| Secondary | Percentage of Participants Meeting the Protocol-defined Nucleos(t)Ide Analog (NA) Treatment Completion Criteria at End of Study Intervention (EOSI) | Percentage of participants meeting the protocol-defined NA treatment completion criteria at EOSI were reported. NA treatment completion criteria are defined based on laboratory results at Week 24 were; HBsAg <10 IU/mL; HBeAg-negative; HBV DNA <20 IU/mL, that is, lower limit of quantification(LLOQ); alanine aminotransferase(ALT) <3*ULN. | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Data for this outcome measure was not planned to be collected and analyzed for Treatment Period 1 and Follow-Up period as pre-specified in protocol. | Posted | | Number | | percentage of participants | | At Week 24 (EOSI) | | | | ID | Title | Description |
|---|
| OG000 | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | Participants who met the eligibility criteria for PegIFN-alpha2a (Participants who did not have disorders including but not limited to: autoimmune disorders, bone marrow suppression, hypoglycemia, hyperglycemia, diabetes mellitus) at Week 12 received combination treatment with JNJ-73763989 200 mg SC injection Q4W along with NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg) QD up to Week 24 plus PegIFN-alpha 2a 180 micrograms (mcg) once weekly (QIW) during TP 2. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after Protocol Amendment 3, received JNJ-73763989 + PegIFN alpha 2a + NA only. |
| |
| Secondary | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Levels Below Different Cut-offs | Percentage of participants with HBeAg levels below different cut-offs were reported. The cut-offs for HBeAg levels were as followed:< 100 IU/mL, < 10 IU/mL, < 1 IU/mL, < LLOQ (0.11 IU/mL). | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. | Posted | | Number | | percentage of participants | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. | |
|
| Secondary | Percentage of Participants With HBsAg Levels Below Different Cut-offs | Percentage of participants with HBsAg levels below different cut-offs were reported. The cut-offs for HBsAg level were: <1000 IU/mL, <100 IU/mL, <10 IU/mL, <1 IU/mL, \ | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. | Posted | | Number | | percentage of participants | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. | | OG001 | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA |
|
| Secondary | Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Below Different Cut-offs | Percentage of participants with HBV DNA levels below cut-offs were reported. The cut-offs for HBV DNA were as follows: \ | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. | Posted | | Number | | percentage of participants | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. | |
|
| Secondary | Percentage of Participants With ALT Levels Greater Than or Equal to (>=) 3*ULN | Percentage of participants with ALT levels below >=3*ULN cut-off were reported. | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. | Posted | | Number | | percentage of participants | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. | | OG001 | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA |
|
| Secondary | Percentage of Participants With HBeAg Seroconversion | Percentage of participants with HBeAg seroconversion were reported. Seroconversion of HBeAg is defined as having achieved HBeAg seroclearance (as HBeAg level \ | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. | Posted | | Number | | percentage of participants | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. |
|
| Secondary | Percentage of Participants With HBsAg Seroconversion | Percentage of participants with HBsAg seroconversion were reported. Seroconversion of HBsAg was defined as having achieved HBsAg seroclearance (defined as HBsAg \ | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. | Posted | | Number | | percentage of participants | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. | |
|
| Secondary | Change From Baseline Over Time in HBsAg Levels | Change from baseline over time in HBsAg levels were reported. The baseline assessment was defined as the last observed non-missing measurement before the date and time of the first administration of any of study agent. | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. | Posted | | Mean | Standard Error | log10 IU/mL | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Baseline (Day 1) up to Week 24; Follow-Up: From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. | | OG001 | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA |
|
| Secondary | Change From Baseline Over Time in HBeAg Levels | Change from baseline over time in HBeAg levels were reported. The baseline assessment was defined as the last observed non-missing measurement before the date and time of the first administration of any of study agent. | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. | Posted | | Mean | Standard Error | log10 IU/mL | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Baseline (Day 1) up to Week 24; Follow-Up: From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. | |
|
| Secondary | Change From Baseline Over Time in HBV DNA Levels | Change from baseline over time in HBV DNA levels were reported. The baseline assessment was defined as the last observed non-missing measurement before the date and time of the first administration of any of study agent. | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. | Posted | | Mean | Standard Error | log10 IU/mL | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Baseline (Day 1) up to Week 24; Follow-Up: From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. | | OG001 | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA |
|
| Secondary | Time to First Occurrence of HBsAg Seroclearance | Time to first occurrence of HBsAg seroclearance were reported in median time. Time to first occurrence of the HBsAg seroclearance was defined as the number of days between the date of first study intervention intake and the date of first occurrence of the HBsAg seroclearance. | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Data for this endpoint was planned to be collected and analyzed in a single arm. | Posted | | Median | Full Range | weeks | | From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | Pooled (JNJ-3989 200mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA) | Participants received JNJ-3989 200 mg as SC Q4W along with JNJ-6379 250 mg tablet QD and NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg QD up to 12 weeks in TP1. At Week 12, participants who met eligibility criteria for PegIFN-alpha 2a entered TP2. Participants in TP2 received combination treatment of JNJ-3989 200 mg SC injection Q4W with NA treatment up to Week 24 plus PegIFN-alpha 2a 180 mcg Q1W. At Week 24, before follow-up period, participants stopped JNJ-3989 + JNJ-6379 + PegIFN-alpha2a. At Week 26, those who met the NA treatment completion criteria stopped NA (follow up Week 2) and those who did not meet criteria continued NA treatment in follow-up period up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4). Participants enrolled until Protocol Amendment 3 (PA3), also received JNJ-6379 250 mg orally as intervention in TP1 and TP2 and those enrolled after PA3, received only JNJ-3989 + PegIFN alpha 2a + NA during study. |
|
| Secondary | Time to First Occurrence of HBeAg Seroclearance | Time to first occurrence of HBeAg seroclearance were reported in median time. Time to first occurrence of the HBeAg seroclearance is defined as the number of days between the date of first study intervention intake and the date of the first occurrence of the HBeAg seroclearance. | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. Data for this outcome measure was planned to be collected and analyzed in a single arm. | Posted | | Median | Full Range | weeks | | From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | Pooled (JNJ-3989 200mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA) | Participants received JNJ-3989 200 mg as SC Q4W along with JNJ-6379 250 mg tablet QD and NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg QD up to 12 weeks in TP1. At Week 12, participants who met eligibility criteria for PegIFN-alpha 2a entered TP2. Participants in TP2 received combination treatment of JNJ-3989 200 mg SC injection Q4W with NA treatment up to Week 24 plus PegIFN-alpha 2a 180 mcg Q1W. At Week 24, before follow-up period, participants stopped JNJ-3989 + JNJ-6379 + PegIFN-alpha2a. At Week 26, those who met the NA treatment completion criteria stopped NA (follow up Week 2) and those who did not meet criteria continued NA treatment in follow-up period up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4). Participants enrolled until Protocol Amendment 3 (PA3), also received JNJ-6379 250 mg orally as intervention in TP1 and TP2 and those enrolled after PA3, received only JNJ-3989 + PegIFN alpha 2a + NA during study. |
|
| Secondary | Time to First Occurrence of HBV DNA < LLOQ | Time to first occurrence of HBV DNA < LLOQ (20 IU/mL) were reported in median time. Time to first occurrence of the HBV DNA < LLOQ is defined as the number of days between the date of first study intervention intake and the date of the first occurrence of the HBV DNA < LLOQ. | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Data for this endpoint was planned to be collected and analyzed in a single arm. | Posted | | Median | Full Range | weeks | | From Baseline (Day 1) up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | Pooled (JNJ-3989 200mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA) | Participants received JNJ-3989 200 mg as SC Q4W along with JNJ-6379 250 mg tablet QD and NA treatment (either ETV 0.5 mg, TDF 245 mg, or TAF 25 mg QD up to 12 weeks in TP1. At Week 12, participants who met eligibility criteria for PegIFN-alpha 2a entered TP2. Participants in TP2 received combination treatment of JNJ-3989 200 mg SC injection Q4W with NA treatment up to Week 24 plus PegIFN-alpha 2a 180 mcg Q1W. At Week 24, before follow-up period, participants stopped JNJ-3989 + JNJ-6379 + PegIFN-alpha2a. At Week 26, those who met the NA treatment completion criteria stopped NA (follow up Week 2) and those who did not meet criteria continued NA treatment in follow-up period up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4). Participants enrolled until Protocol Amendment 3 (PA3), also received JNJ-6379 250 mg orally as intervention in TP1 and TP2 and those enrolled after PA3, received only JNJ-3989 + PegIFN alpha 2a + NA during study. |
|
| Secondary | Percentage of Participants With Virologic Breakthrough | Percentage of Participants with virologic breakthrough were reported. It was defined as confirmed on-treatment (the time period during which the participant received any of the study treatments) HBV DNA increase by >1 log10 IU/mL from nadir or confirmed on-treatment HBV DNA level >200 IU/mL in participants who had HBV DNA level \ | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. | Posted | | Number | | percentage of participants | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. |
|
| Secondary | Percentage of Participants With HBsAg Seroclearance at Week 48 Without Re-starting NA Treatment | Percentage of participants with HBsAg seroclearance at Week 48 (i.e., 24 weeks after completion of all study interventions at Week 24) without re-starting NA treatment were reported. HBsAg seroclearance was defined as [quantitative] HBsAg \ | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Data for this outcome measure was planned to be collected and analyzed for Follow-Up Period only as pre-specified in protocol. | Posted | | Number | | percentage of participants | | At Week 48 (24 weeks after completion of all study interventions at Week 24) | | | | ID | Title | Description |
|---|
| OG000 | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen [HBsAg] <10 international units/millilitre [IU/mL], and hepatitis B e antigen [HBeAg]-negative, and hepatitis B virus deoxyribonucleic acid [HBV DNA] <20 IU/mL \ |
| |
| Secondary | Percentage of Participants With HBV DNA < LLOQ at Week 48 Without Re-starting NA Treatment | Percentage of participants with HBV DNA \ | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. Data for this outcome measure was planned to be collected and analyzed for Follow-Up Period only as pre specified in protocol. | Posted | | Number | | percentage of participants | | At Week 48 (24 weeks after completion of all study interventions at Week 24) | | | | ID | Title | Description |
|---|
| OG000 | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen [HBsAg] <10 international units/millilitre [IU/mL], and hepatitis B e antigen [HBeAg]-negative, and hepatitis B virus deoxyribonucleic acid [HBV DNA] <20 IU/mL \ |
| |
| Secondary | Percentage of Participants With Biochemical Flares | Percentage of participants with biochemical flares were reported. On-treatment biochemical flare was defined as confirmed ALT and/or AST >=3*ULN and >=3*nadir, while the participant received any of the study interventions. Off-treatment biochemical flare was defined as confirmed ALT and/or AST =3*ULN and =3*nadir, while the participants did not receive any of the study interventions (Off treatment, including NA). | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure and "n"(number analyzed) signifies number of participants analyzed at specified categories. No participant was available for the analysis where "n=0". | Posted | | Number | 90% Confidence Interval | percentage of participants | | Treatment Period 1: From Baseline (Day 1) up to Week 12; Treatment Period 2: From Week 12 up to Week 24; Follow-Up: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. |
|
| Secondary | Percentage of Participants With Virologic Flares | Percentage of participants with virologic flares were reported. Virologic flare was defined as confirmed HBV DNA >peak threshold (lowest peak to qualify as virologic flare was HBV DNA >200 IU/mL) in participants who were off-treatment. Off-treatment was defined as the time period after stopping all study treatments (including NA) and had HBV DNA \ | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. Data for this outcome measure was planned to be collected and analyzed for Follow-Up period only as pre-specified in protocol. | Posted | | Number | 90% Confidence Interval | percentage of participants | | Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen [HBsAg] <10 international units/millilitre [IU/mL], and hepatitis B e antigen [HBeAg]-negative, and hepatitis B virus deoxyribonucleic acid [HBV DNA] <20 IU/mL \ |
|
| Secondary | Number of Participants Requiring NA Re-treatment | Number of participants requiring NA re-treatment based on failure in NA treatment completion criteria (HBsAg <10 IU/mL, and HBeAg-negative, and HBV DNA < LLOQ (20 IU/mL), and ALT <3*ULN) were reported. | FAS included all participants who were enrolled and who received at least 1 dose of study intervention within this ISA. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. Data for this outcome measure was planned to be collected and analyzed for Follow-up Period only as pre-specified in protocol. | Posted | | Count of Participants | | Participants | | Follow-Up Period: From Week 24 up to follow-up Week 48 (with window period of +/- 4 days, that is Week 72.4) | | | | ID | Title | Description |
|---|
| OG000 | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | At Week 24, prior to follow-up period, all participants stopped treatment with JNJ-73763989 + JNJ-56136379 + PegIFN-alpha2a. Participants who met the protocol-defined NA treatment completion criteria (hepatitis B surface antigen [HBsAg] <10 international units/millilitre [IU/mL], and hepatitis B e antigen [HBeAg]-negative, and hepatitis B virus deoxyribonucleic acid [HBV DNA] <20 IU/mL \ |
| |
| Secondary | Maximum Observed Plasma Concentration (Cmax) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924) | The maximum observed plasma concentrations (Cmax) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924) were reported. | Pharmacokinetics(PK) analysis set included participants who received at least 1 dose of study intervention and had at least 1 valid blood sample drawn for PK analysis. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. Data for this outcome measure was planned to be collected and analyzed for TP1 and TP2 only as specified in protocol. | Posted | | Mean | Standard Deviation | nanograms/milliliters (ng/mL) | | Treatment Period 1: Day 1 Week 1; Treatment Period 2: Day 1, Week 12 | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. | | OG001 |
|
| Secondary | Plasma Concentration 24 Hours After Administration (C24h) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924) | Plasma concentration 24 hours (C24h) after administration of JNJ-73763989 (JNJ-73763976 and JNJ-73763924) were reported. | PK Analysis Set included all participants who received at least 1 dose of study intervention and had at least 1 valid blood sample drawn for PK analysis. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. Data for this outcome measure was planned to be collected and analyzed for TP 1 and TP 2 as pre-specified in protocol. | Posted | | Mean | Standard Deviation | ng/mL | | Treatment Period 1: Day 1 Week 1; Treatment Period 2: Day 1, Week 12 | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. | | OG001 |
|
| Secondary | Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924) | Time to reach maximum observed plasma concentration (Cmax) (Tmax) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924) were reported. | PK analysis set included all participants who received at least 1 dose of study intervention and had at least 1 valid blood sample drawn for PK analysis. Here "N" (Number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. Data for this outcome measure was planned to be collected and analyzed for TP1 and TP2 as pre-specified in protocol. | Posted | | Median | Full Range | hours | | Treatment Period 1: Day 1, Week 1; Treatment Period 2: Day 1, Week 12 | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. | | OG001 |
|
| Secondary | Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hour (AUC[0-24]h) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924) | Area under the plasma concentration versus time curve from time 0 to 24 hours (AUC[0-24]h) of JNJ-73763989 (JNJ-73763976 and JNJ-73763924) were reported. | PK analysis set: participants who received at least 1 dose of study intervention and had at least 1 valid blood sample drawn for PK analysis. Here "N" (number of participants analyzed) signifies the number of participants that were evaluable for this outcome measure. Data for this outcome measure was planned to be collected and analyzed for TP1 and TP2 as specified in protocol. | Posted | | Mean | Standard Deviation | ng*h/mL | | Treatment Period 1: Day 1, Week 1; Treatment Period 2: Day 1, Week 12 | | | | ID | Title | Description |
|---|
| OG000 | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Participants received a single dose of JNJ-73763989 (JNJ-3989) 200 milligrams (mg) as a subcutaneous injection (SC) every 4 weeks (Q4W) along with JNJ-56136379 (JNJ-6379) 250 mg tablet once daily (QD) and nucleos(t)ide analog (NA) treatment (either entecavir[ETV] 0.5 mg, tenofovir disoproxil fumarate[TDF] 245 mg, or tenofovir alafenamide[TAF] 25 mg) QD up to 12 weeks in TP 1. Participants enrolled until Protocol Amendment 3, also received single dose of JNJ-56136379 250 mg orally as part of their study intervention. Participants enrolled after protocol amendment 3, received JNJ-3989 + PegIFN-alpha 2a + NA only. Participants were assessed for eligibility criteria for PegIFN-alpha 2a at Week 12. Participants who met the criteria entered TP 2. | |
|